NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
06/27/2026
Back to search
Official data from USPTO
NANO-OJAS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
07/21/2026
Trademark type
Word
Nice classes
5
Filing date
06/16/2016
Registration date
12/20/2016
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/27/2026
Last transaction
07/21/2026
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
05/21/2014
First use in commerce
05/21/2014
Drawing code
4
Owner type
03
Owner location
Chappaqua, NY, US
Examiner
KUNG, KAELIE ELIZABETH
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NANORX INC.
Representatives
Scott D. Locke Dorf Nelson & Zauderer LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Analgesic and muscle relaxant nutraceutical preparations; Anti-diabetic nutraceuticals; Cardiovascular nutraceuticals; Nutraceutical preparations for the treatment of gout; Nutraceutical preparations and substances for the treatment of gastro-intestinal diseases; Nutraceutical preparations and substances for the treatment of infectious diseasesblood disorderspaininflammationsepsisalopeciaobesity and cognitive disorders; Nutraceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Nutraceutical preparations for inhalation for the treatment of pulmonary hypertension; Nutraceutical preparations for the prevention and treatment of disorders of the nervous systemthe immune systemthe cardio-vascular systemthe metabolic systemthe respiratory systemthe musculo-skeletal systemthe genitourinary system; Nutraceutical preparations for the treatment of inflammatory disorders; Nutraceutical preparations for use in dermatologyoncologyhematology and in tissue and organ transplantationin ophthalmology and for gastroenterological disorders; Nutraceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Nutraceutical preparations for the prevention of diabetes; Nutraceutical preparations for the treatment of eye diseases and conditions; Nutraceutical preparations for the treatment of heart rhythm disorders; Nutraceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Nutraceutical preparations for the treatment of infectious diseases; Nutraceutical preparations for the treatment of hypertension; Nutraceutical preparations for treating allergic rhinitis and asthma; Nutraceutical preparations for treating diabetes; Nutraceutical preparations for treating skin disorders; Nutraceutical preparations for use in urology; Nutraceutical preparationsa blood clotting aid and delivery system for use in human and veterinary medicine; Nutraceutical products for ophthalmological use; Nutraceutical products for the treatment of bone diseases; Nutraceutical products for the treatment of joint disease; Nutraceutical products for the treatment of viral and infectious diseases; Nutraceutical preparations for the treatment of cancer; Nutraceutical products for treating respiratory diseases and asthma; Nutraceutical solutions used in dialysis; Nutraceuticalslipid lowering agents; Plant extracts for medicalveterinary and nutraceutical purposes; Therapeutic nutraceuticals for the treatment of obesity
Publications
History of USPTO decisions and trademark events.
29 publications found
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/27/2026
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
06/27/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/27/2026
E89R
TEAS SECTION 8 & 9 RECEIVED
04/27/2026
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
12/20/2025
NA85
NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
05/18/2023
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
05/18/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
05/18/2023
E815
TEAS SECTION 8 & 15 RECEIVED
11/03/2022
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
12/20/2021
R.PR
REGISTERED-PRINCIPAL REGISTER
12/20/2016
CHPB
POST PUBLICATION AMENDMENT - ENTERED
10/05/2016
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/04/2016
PUBO
PUBLISHED FOR OPPOSITION
10/04/2016
DOCK
ASSIGNED TO EXAMINER
10/04/2016
APET
ASSIGNED TO PETITION STAFF
09/27/2016
EPPA
TEAS POST PUBLICATION AMENDMENT RECEIVED
09/15/2016
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/14/2016
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
08/30/2016
ALIE
ASSIGNED TO LIE
08/30/2016
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/15/2016
XAEC
EXAMINER'S AMENDMENT ENTERED
08/15/2016
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
08/15/2016
GNEA
EXAMINERS AMENDMENT E-MAILED
08/15/2016
CNEA
EXAMINERS AMENDMENT -WRITTEN
08/15/2016
DOCK
ASSIGNED TO EXAMINER
08/15/2016
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/22/2016
NWAP
NEW APPLICATION ENTERED
06/20/2016
Continuous trademark protection
Get notified about every new filing that threatens NANO-OJAS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.